SMO and Hepatic fibrosis: Given that GSK3B is one of the targets of ILK29, 46, it is possible that TB4-dependent activation of ILK and concomitant repression of pGSK3B increases Hh signaling by promoting the activation of SMO-GLI2, resulting in the activation of quiescent HSCs during liver fibrosis.